Leerink Partnrs Issues Optimistic Estimate for UTHR Earnings

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Equities researchers at Leerink Partnrs boosted their Q3 2025 EPS estimates for shares of United Therapeutics in a research note issued to investors on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will post earnings of $8.50 per share for the quarter, up from their prior forecast of $8.08. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share. Leerink Partnrs also issued estimates for United Therapeutics' FY2025 earnings at $29.96 EPS, FY2026 earnings at $30.99 EPS, FY2027 earnings at $30.46 EPS and FY2028 earnings at $31.87 EPS.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. During the same quarter in the previous year, the company earned $6.17 EPS. United Therapeutics's quarterly revenue was up 17.2% compared to the same quarter last year.

A number of other research analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price target for the company in a research note on Monday, April 21st. Morgan Stanley boosted their price target on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research note on Thursday, May 1st. Wells Fargo & Company restated an "equal weight" rating and set a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Finally, JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $393.00.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded up $6.11 during trading on Friday, reaching $325.82. 317,040 shares of the company traded hands, compared to its average volume of 439,500. United Therapeutics has a 1-year low of $266.98 and a 1-year high of $417.82. The company has a 50 day moving average price of $301.06 and a 200-day moving average price of $333.58. The firm has a market capitalization of $14.70 billion, a PE ratio of 14.31, a P/E/G ratio of 0.97 and a beta of 0.57.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors have recently added to or reduced their stakes in UTHR. Caprock Group LLC grew its position in United Therapeutics by 16.3% during the fourth quarter. Caprock Group LLC now owns 792 shares of the biotechnology company's stock valued at $279,000 after buying an additional 111 shares during the period. Meritage Portfolio Management grew its position in United Therapeutics by 12.2% during the fourth quarter. Meritage Portfolio Management now owns 1,446 shares of the biotechnology company's stock valued at $510,000 after buying an additional 157 shares during the period. Bleakley Financial Group LLC grew its position in United Therapeutics by 58.1% during the fourth quarter. Bleakley Financial Group LLC now owns 1,059 shares of the biotechnology company's stock valued at $374,000 after buying an additional 389 shares during the period. Livforsakringsbolaget Skandia Omsesidigt grew its position in United Therapeutics by 6,925.0% during the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 28,100 shares of the biotechnology company's stock valued at $9,904,000 after buying an additional 27,700 shares during the period. Finally, Newbridge Financial Services Group Inc. bought a new position in United Therapeutics during the fourth quarter valued at about $25,000. Institutional investors own 94.08% of the company's stock.

Insider Transactions at United Therapeutics

In other news, Director Raymond Dwek sold 4,000 shares of the company's stock in a transaction on Monday, April 7th. The shares were sold at an average price of $284.55, for a total value of $1,138,200.00. Following the completion of the sale, the director now owns 1,750 shares in the company, valued at $497,962.50. This represents a 69.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $316.07, for a total transaction of $3,476,770.00. Following the transaction, the executive vice president now owns 36,781 shares of the company's stock, valued at approximately $11,625,370.67. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 56,500 shares of company stock worth $16,923,950 in the last quarter. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.